haemophagocyt
syndrom
hp
haemophagocyt
lymphohistiocytosi
hlh
rare
diseas
caus
dysfunct
cytotox
cell
nk
cell
cellnk
cell
dysregul
caus
aberr
cytokin
releas
result
proliferationactiv
histiocyt
subsequ
haemophagocytosi
histiocyt
infiltr
reticuloendotheli
system
result
hepatomegali
splenomegali
lymphadenopathi
pancytopenia
ultim
lead
multipl
organ
dysfunct
common
clinic
featur
includ
high
fever
despit
broad
spectrum
antimicrobi
maculopapular
rash
neurolog
symptom
coagulopathi
abnorm
liver
function
test
haemophagocyt
syndrom
either
primari
ie
due
underli
genet
defect
secondari
associ
malign
autoimmun
diseas
also
call
macrophag
activ
syndrom
infect
infecti
trigger
commonli
due
viral
infect
mainli
herp
group
ebv
common
caus
hp
fatal
untreat
earli
recognit
clinic
present
laboratori
abnorm
associ
hp
prompt
initi
treatment
life
save
hp
trigger
viral
infect
gener
respond
specif
antivir
therapi
may
treat
immunosuppressiveimmunomodulatori
agent
refractori
case
bone
marrow
transplant
haemophagocyt
syndrom
hp
also
call
haemophagocyt
lymphohistiocytosi
hlh
characteris
impair
absent
activ
nk
cell
cytotox
tcell
lead
cytokin
dysregul
prolifer
activ
histiocyt
hp
result
multiorgan
dysfunct
haemophagocytosi
within
reticuloendotheli
system
characteris
pancytopenia
organomegali
untreat
hp
fatal
hp
first
describ
scott
robbsmith
term
histiocyt
medullari
reticulosi
virusassoci
hp
vah
first
characteris
risdal
case
seri
patient
incid
hp
difficult
estim
sinc
syndrom
certainli
underdiagnos
nationwid
survey
hp
japan
larg
number
hp
studi
done
report
annual
incid
hp
divid
primari
genet
hp
secondari
reactiv
hp
tabl
primari
hp
usual
occur
earli
life
associ
higher
mortal
rate
secondari
hp
occur
later
life
gener
carri
better
prognosi
distinct
categor
primari
hp
occur
later
life
may
trigger
infect
may
associ
typic
genet
mutat
famili
form
hlh
fhlh
first
describ
farquhar
claireaux
fhlh
autosom
recess
disord
estim
occur
birth
case
manifest
first
year
life
form
genet
hp
associ
immun
defici
syndrom
includ
chediakhigashi
syndrom
griscelli
syndrom
xlink
lymphoprolif
syndrom
xlp
wiskottaldrich
syndrom
sever
combin
immunodefici
lysinur
protein
intoler
hermanskypudlak
syndrom
true
incid
reactiv
hp
difficult
defin
reactiv
hp
divid
three
categori
macrophag
activ
syndrom
associ
autoimmun
diseas
malign
associ
hlh
especi
lymphomaassoci
haemophagocyt
syndrom
infect
associ
hlh
iah
iah
commonli
associ
viral
infect
focu
review
iah
also
caus
bacteri
infect
includ
mycobacteria
spirochet
well
fungal
parasit
pathogen
review
publish
case
children
diagnos
iah
found
half
far
east
ebv
trigger
viru
children
infecti
agent
identifi
overal
mortal
higher
patient
ebvhp
haemophagocyt
disord
aris
defect
critic
regulatori
pathway
respons
natur
termin
immun
inflammatori
respons
subsequ
failur
homeostat
remov
cell
superflu
danger
host
organ
role
granul
perforingranzym
mediat
cytotox
import
kill
infect
cell
termin
immun
respons
genet
hp
attribut
defect
mechan
granul
perforingranzym
mediat
cytotox
sever
genet
loci
relat
activ
perforingranzym
granul
implic
pathophysiolog
genet
hp
defect
trigger
apoptosi
fhlh
also
describ
refer
specif
gene
mutat
associ
primari
hp
includ
gene
perforin
munc
famili
gene
syntaxin
gene
contain
gene
pathophysiolog
acquir
hp
fulli
understood
certainli
involv
interact
cell
macrophag
exclud
genet
predisposit
affect
case
persist
activ
lymphocyt
result
uncontrol
immun
respons
caus
hypersecret
proinflammatori
cytokin
ifn
tnf
macrophagecolonystimul
factor
mcsf
appear
play
crucial
role
particularli
autoimmun
relat
hp
addit
higher
level
ifn
associ
wors
prognosi
childhood
hp
activ
lymphocyt
also
result
elev
solubl
receptor
one
diagnost
criteria
hp
correl
prognosi
furthermor
presenc
specif
tnf
polymorph
associ
increas
suscept
reactiv
hp
certain
asian
popul
prolifer
histiocyt
characteris
upregul
adhes
mhc
class
ii
molecul
monocytesmacrophag
expans
inflammatori
monocyt
increas
express
persist
activ
lymphocyt
prolifer
histiocyt
lead
organ
infiltr
hemophagocytosi
variou
blood
cell
macrophag
present
bone
marrow
lymph
node
spleen
diagnosi
hp
reli
specif
clinic
laboratori
histopatholog
find
propos
histiocyt
societi
updat
tabl
main
symptom
sign
hp
prolong
high
fever
splenomegali
cytopenia
involv
two
cell
line
less
frequent
observ
clinic
find
includ
jaundic
hepatomegali
lymphadenopathi
rash
neurolog
sign
tabl
common
laboratori
find
result
promin
liver
dysfunct
low
fibrinogen
level
high
bilirubin
level
elev
serum
transaminas
elev
prothrombin
partial
thromboplastin
time
high
triglycerid
level
common
hp
therefor
includ
diagnost
criteria
studi
patient
secondari
hp
hypertrigyceridemia
diagnosi
time
diseas
process
triglycerid
level
subsequ
decreas
success
treatment
hp
often
strike
elev
ferritin
level
characterist
though
found
diseas
studi
texa
found
ferritin
level
mgl
sensit
specif
hp
two
main
diagnost
paramet
increas
plasma
concentr
alpha
chain
receptor
impair
nk
cell
activ
typic
histopatholog
find
includ
activ
macrophag
engulf
leukocyt
erythrocyt
platelet
precursor
cell
haemophagocytosi
seen
organ
particularli
common
bone
marrow
lymph
node
liver
spleen
eventu
result
organomegali
organ
failur
present
hemophagocytosi
found
minor
case
easili
detect
syndrom
progress
therefor
haemophagocytosi
absent
initi
biopsi
specimen
biopsi
may
need
repeat
case
high
suspicion
diagnosi
hp
establish
one
two
follow
criteria
fulfil
molecular
diagnosi
consist
hp
ie
prf
mutat
sap
mutat
mutat
five
eight
follow
criteria
clinic
fever
splenomegali
laboratori
cytopenia
affect
cell
lineag
hemoglobin
gdl
platelet
neutrophil
elev
triglycerid
level
mgdl
andor
low
fibrinogen
level
mgdl
elev
ferritin
level
ngml
histopatholog
hemophagocytosi
without
evid
malign
biolog
marker
low
absent
nk
cell
cytotox
elev
solubl
chain
criteria
ad
previou
hlh
diagnost
guidelin
viru
associ
haemophagocyt
syndrom
viru
associ
haemophagocyt
syndrom
diagnosi
hp
establish
search
underli
diseas
genet
rheumatolog
malign
diseas
possibl
infecti
trigger
perform
treatment
hp
frequent
fatal
treat
promptli
earli
therapi
hp
life
save
diagnost
criteria
may
becom
appar
late
diseas
necessari
fulfil
diagnost
criteria
initi
therapi
treatment
base
control
cytokin
storm
cellular
prolifer
iah
treatment
underli
infecti
trigger
suffici
control
diseas
especi
hp
associ
ebv
immunochemotherapi
propos
histiocyt
societi
protocol
subsequ
protocol
consist
combin
therapi
etoposid
dexamethason
cyclosporin
well
select
patient
intrathec
therapi
methotrex
corticosteroid
protocol
found
highli
effect
earli
seri
case
ebvhp
efficaci
later
confirm
larg
seri
includ
patient
ebvhp
none
patient
receiv
four
dose
etoposid
die
prompt
use
etoposid
less
week
diagnosi
greatli
improv
outcom
pediatr
adult
patient
use
cyclosporin
treat
hp
first
suggest
oyama
et
al
found
reduc
rate
fatal
infect
associ
neutropenia
although
immunemodul
chemotherapi
effect
commonli
associ
side
effect
pronounc
follow
prolong
cours
treatment
cyclosporin
associ
sever
headach
hypertens
seizur
renal
impair
corticosteroid
mani
welldescrib
advers
effect
includ
hyperglycemia
fluid
retent
hypertens
weight
gain
etoposid
associ
myelosuppress
develop
secondari
leukemia
intraven
gamma
immunoglobulin
ivig
use
without
corticosteroid
treat
hp
usual
effect
monotherapi
seventeen
patient
treat
ivig
ae
corticosteroid
switch
etoposidebas
regimen
better
control
diseas
year
surviv
ivig
corticosteroid
group
compar
group
receiv
etoposid
contain
regimen
first
line
therapi
use
growth
factor
granulocyt
g
csf
granulocyt
monocyt
gm
csf
gener
recommend
exacerb
hp
haematopoiet
stem
cell
transplant
hsct
recommend
patient
genet
form
patient
recurr
persist
refractori
sever
diseas
hsct
greatli
improv
surviv
fhlh
retrospect
review
fhlh
year
ago
describ
mean
surviv
less
month
onset
symptom
year
overal
surviv
less
current
definit
treatment
potenti
cure
fhlh
achiev
hsct
project
year
surviv
rate
rang
arico
et
al
review
patient
fhlh
bone
marrow
transplant
bmt
recipi
significantli
superior
outcom
comparison
nontranspl
patient
versu
surviv
rate
combin
chemotherapi
bmt
treat
patient
probabl
surviv
year
case
ebv
epidemiolog
epsteinbarr
viru
ebv
ubiquit
herpesviru
associ
case
infect
associ
hp
epidemiolog
ebv
associ
hpshlh
ebvhp
ebvhlh
well
known
ebvhp
higher
incid
asian
countri
year
japan
case
ebv
hp
diagnos
femal
predomin
peak
incid
year
age
higher
incid
rate
asian
countri
theoris
due
pathogen
viral
strain
ebv
genet
similar
viral
strain
obtain
nasopharyng
carcinoma
cell
line
ebvhp
describ
western
countri
preval
nonasian
popul
may
underestim
inform
epidemiolog
ebvhp
adult
lack
primari
ebv
infect
usual
asymptomat
expect
infecti
mononucleosi
im
seen
commonli
children
young
adult
primari
infect
ebv
typic
infect
replic
b
cell
primari
infect
ebvspecif
cell
cytotox
cell
ctl
usual
acquir
regul
ebvinfect
b
cell
induc
memori
b
cell
ebv
welldescrib
tropism
b
cell
nasopharyng
epitheli
cell
invas
nonb
cell
popul
play
import
role
pathogenesi
sever
sever
ebv
relat
diseas
diseas
manifest
gener
depend
type
ebvinfect
cell
state
host
immun
rare
case
instanc
refractori
sever
ebv
diseas
result
either
chronic
activ
ebv
infect
ii
acut
fulmin
ebv
hp
iii
lymphoprolif
disord
tnk
cell
leukemialymphoma
lymphoma
associ
haemophagocyt
syndrom
chronic
ebv
infect
primarili
cell
nk
cell
affect
dysfunct
tnk
cell
result
decreas
ebvspecif
ctl
subsequ
ebvassoci
nk
cell
lymphoprolif
diseas
ebvhp
ebv
infect
primarili
cell
result
cytokin
storm
releas
proinflammatori
cytokin
includ
tnf
ifn
result
secondari
activ
histiocyt
macrophag
cytokin
respons
seen
ebvhp
tend
much
pronounc
one
observ
nonebvhp
although
ebvhp
probabl
develop
result
element
immun
dysfunct
precis
characterist
host
vulner
ebv
larg
unknown
major
ebvhp
case
occur
appar
immunocompet
previous
healthi
children
adolesc
young
adult
case
ebvhp
also
seen
set
establish
immun
defici
fhlh
xlp
serolog
test
help
determin
ebvhp
occur
set
primari
infect
result
reactiv
process
recent
epidemiolog
studi
japan
vast
major
ebvhp
case
occur
children
primari
infect
reactiv
consid
risk
factor
wors
outcom
howev
serolog
method
carri
limit
realtim
pcr
allow
quantit
measur
ebv
viral
load
even
though
vast
major
ebv
peripher
blood
found
within
leukocyt
ebv
pcr
whole
blood
serum
consid
adequ
reflect
ebv
load
term
viral
replic
ebv
pcr
level
ebvhp
usual
higher
seen
ebvim
ebv
viral
load
consid
prognost
factor
measur
efficaci
treatment
ebvhp
variou
cell
sort
techniqu
use
determin
cell
nk
cell
primarili
involv
confirm
diagnosi
clonal
determin
cytogenet
analysi
tcell
receptor
gene
rearrang
southern
blot
analysi
fuse
termini
ebv
genom
utilis
blood
bone
marrow
lymphoid
tissu
genet
test
inherit
condit
link
hemophagocytosi
famili
hlh
xlp
consid
particularli
young
year
age
male
patient
ebvhp
consanguin
parent
hp
present
anoth
sibl
hp
relaps
refractori
mild
case
ebvhp
treat
conserv
sinc
spontan
regress
ebvhp
describ
refer
antivir
therapi
acyclovir
ganciclovir
cidofovir
gener
ineffect
im
provid
disappoint
result
ebvhp
optim
treatment
strategi
ebvhp
consist
control
cytokin
storm
result
multiorgan
failur
coagulopathi
antithymocyt
globulin
splenectomi
plasma
exchang
blood
exchang
transfus
use
treatment
ebvhp
ii
control
opportunist
infect
particularli
fungal
bacteri
infect
set
neutropenia
iii
erad
prolifer
clonal
ebv
contain
cell
nk
cell
immunosupviru
associ
haemophagocyt
syndrom
viru
associ
haemophagocyt
syndrom
pressiv
medic
inhibit
overact
nk
cell
respons
conjunct
chemotherapeut
agent
target
divid
lymphocyt
mononuclear
phagocyt
typic
use
treat
ebvhp
earli
treatment
associ
markedli
improv
surviv
addit
agent
elimin
ebv
infect
b
cell
may
decreas
ebv
viral
load
improv
efficaci
current
therapeut
arsen
ineffect
alon
rituximab
humanis
monoclon
antibodi
target
matur
b
cell
ad
standard
regimen
treat
case
ebvhp
hsct
bmt
becom
treatment
choic
hlh
well
refractori
case
ebvhp
ebvhp
carri
worst
prognosi
among
viral
infect
associ
hp
howev
use
protocol
necessari
bmt
prognosi
ebvhp
improv
dramat
patient
ebvhp
treat
aliv
follow
median
followup
month
patient
treat
etoposidebas
regimen
bmt
experienc
relaps
asid
ebv
common
herpesvirus
associ
hp
cmv
cmv
infect
associ
hp
cmvah
differ
set
observ
healthi
patient
prematur
infant
patient
inflammatori
bowel
diseas
rheumatolog
diseas
cancer
transplant
recipi
prospect
studi
patient
undergo
hsct
develop
hp
cmv
common
trigger
case
use
cmv
hyperimmun
globulin
foscarnet
ganciclovir
associ
recoveri
select
case
younger
age
may
associ
wors
prognosi
fatal
outcom
occur
four
five
infant
hlh
japanes
registri
cmvah
diagnos
less
year
old
associ
hp
mostli
set
kaposi
sarcoma
multicentr
castleman
diseas
lymphoprolif
disord
immunocompromis
host
hiv
transplant
rare
immunocompet
host
prospect
cohort
patient
castleman
diseas
hiv
hp
interestingli
seri
cytokin
level
mani
known
inflammatori
marker
elev
howev
ifn
increas
studi
patient
recov
treatment
splenectomi
etoposid
rituximab
base
regimen
ganciclovir
foscarnet
also
associ
recoveri
case
herpesvirus
except
associ
hp
hiv
hp
associ
hiv
infect
seen
sever
differ
set
case
report
acut
late
hiv
infect
conjunct
immun
reconstitut
inflammatori
syndrom
iri
set
infect
opportunist
non
opportunist
malign
even
though
hemophagocytosi
observ
autopsi
case
hiv
posit
patient
clinic
appar
hp
rare
set
associ
howev
may
underreport
underdiagnos
sinc
hiv
hp
share
mani
similar
clinic
biolog
find
best
knowledg
case
acut
hiv
hp
report
literatur
male
predomin
f
median
age
onset
almost
two
third
count
cellsml
rang
cellsml
treatment
consist
mainli
ivig
n
steroid
n
highli
activ
antiretrovir
therapi
haart
initi
acut
phase
case
case
report
literatur
surviv
review
hivhp
case
bhatia
colleagu
male
median
age
year
rang
less
cellsml
mean
cellsml
lower
count
associ
wors
prognosi
eleven
patient
opportunist
infect
malign
suggest
possibl
pathogenet
role
hiv
patient
present
fever
two
third
hepatomegali
half
splenomegali
pancytopenia
common
inform
avail
n
regard
treatment
three
receiv
haart
one
respond
haart
two
receiv
chemotherapi
inconsist
hlh
protocol
six
receiv
ivig
five
receiv
corticosteroid
two
underw
splenectomi
overal
recoveri
note
patient
half
death
occur
within
month
follow
diagnosi
hp
four
case
hivah
describ
set
iri
patient
male
report
age
rang
year
symptom
occur
within
week
follow
initi
haart
iri
hivhp
occur
set
histoplasmosi
well
hodgkin
lymphoma
patient
hodgkin
lymphoma
treat
chemotherapi
one
surviv
patient
histoplasmosi
surviv
follow
treatment
ivig
amphotericin
fourth
patient
fatal
outcom
despit
treatment
etoposid
corticosteroid
associ
hp
influenza
describ
immunocompromis
immunocompet
patient
prospect
pediatr
studi
one
fatal
case
hp
observ
among
children
hospitalis
season
influenza
influenza
associ
hp
seen
season
avian
swine
nonpandem
influenza
patient
sever
avian
influenza
infect
symptom
laboratori
find
similar
seen
hp
mainli
enceph
organ
dysfunct
haemophagocytosi
bone
marrow
failur
cytokin
storm
haemophagocytosi
seen
autopsi
biopsi
common
characterist
patholog
find
haemagglutinin
found
virus
may
suppress
perforin
express
reduc
cytotox
human
cell
includ
abil
kill
cell
lead
mark
lymphoprolifer
ifnhyperproduct
macrophag
overactiv
virus
resist
amantadin
less
commonli
even
certain
neuraminidas
inhibitor
sinc
mani
similar
exist
hp
sever
flu
infect
author
specul
use
modifi
protocol
shorter
cours
etoposid
dexamethason
consid
infect
associ
hp
one
fatal
case
swine
flu
associ
hp
immunocompet
patient
report
possibl
fatal
case
novel
swineorigin
pandem
strain
could
also
due
hp
current
unclear
much
hp
contribut
patholog
sever
novel
approxim
case
parvoviru
infect
associ
hp
common
underli
diseas
hereditari
spherocytosi
half
patient
femal
case
seen
adolesc
adult
major
patient
parvovirusassoci
hp
surviv
without
specif
therapi
suggest
parvovirusassoci
hp
carri
better
prognosi
vah
viral
hepat
fulmin
viral
hepat
may
mimic
also
caus
true
hp
hepat
viru
commonli
associ
hp
hepat
viru
includ
hepat
b
hepat
c
fifteen
case
havhp
describ
literatur
except
case
report
asia
age
rang
year
median
age
gender
predilect
note
three
patient
concurr
rheumatolog
diseas
system
juvenil
idiopath
arthriti
still
diseas
two
patient
also
hepat
c
one
patient
alcohol
four
patient
receiv
specif
treatment
surviv
commonli
treatment
consist
corticosteroid
ae
ivig
eleven
case
favour
outcom
case
enterovirusassoci
hp
describ
english
literatur
case
occur
infant
less
year
age
oldest
patient
year
old
underli
diseas
found
case
hodgkin
lymphoma
nonhodgkin
lymphoma
acut
lymphoblast
leukemia
juvenil
arthriti
associ
higher
fatal
rate
ten
patient
receiv
ivig
six
combin
steroid
overal
seven
patient
surviv
viru
associ
haemophagocyt
syndrom
viru
associ
haemophagocyt
syndrom
virus
found
associ
hp
includ
adenoviru
bk
viru
measl
mump
rubella
parainfluenza
viru
dengu
hantaviru
hemorrhag
fever
sever
acut
respiratori
syndrom
associ
coronaviru
haemophagocyt
syndrom
rare
often
fatal
diseas
frequent
trigger
viral
infect
notabl
ebv
treatment
underli
infecti
trigger
alon
tend
lead
suboptim
result
earli
recognit
prompt
treatment
shown
improv
prognosi
sever
case
often
requir
chemotherapi
without
bmt
clinician
therefor
need
alert
suspect
entiti
patient
high
fever
respond
broadspectrum
antibiot
organomegali
characterist
laboratori
histolog
find
